Tamarind Bio
-100%
est. 2Y upside i
AI Inference Platform for Drug Discovery
Rank
#3839
Sector
Biotech SaaS
Est. Liquidity
~6Y
Data Quality
Data: LowCurrent equity is deeply underwater based on the valuation implied by the Series A round ($37M post) relative to very low revenue ($440k) and slow growth (7%).
Last updated: July 3, 2026
Exit multiple expands to 10x on partnership momentum, but projected revenue $485k yields exit value $4.85M, still below $14.1M preference stack, common recovers zero.
Exit multiple normalizes to 5x, exit value $2.425M, well below total funding, common gets nothing.
Multiple compresses to 2x and revenue disappoints, exit value $0.97M, common recovers -100%.
Preference Stack Risk
severeFunding Intensity
38%Total funding $14.1M vs entry valuation $37M gives 38% overhang, meaning preferred shareholders take nearly all proceeds in exits below $14.1M.
Dilution Risk
highWith only $440k ARR and 18 employees, the company likely needs another round within 18-24 months, diluting current common by 20%+.
Secondary Liquidity
noneNo secondary market activity detected.
Engineering — 2 roles
- Infrastructure Engineer · San Francisco
- Software Engineer · San Francisco
Science — 1 role
- Computational Scientist · San Francisco
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Tamarind Bio's data — designed to show you've done your homework.
- 1
“How do you plan to accelerate revenue growth from current 7% YoY?”
- 2
“What is the company's path to profitability and cash flow break-even?”
- 3
“Given the equity is likely worthless in a 2-year horizon, what is the retention strategy for key hires?”
Community
Valuation Sentiment
Our model estimates -100% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.